Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.

Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M.

Anticancer Res. 2013 Apr;33(4):1387-95.

PMID:
23564777
2.

Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.

Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G.

PLoS One. 2013 Jun 12;8(6):e65569. doi: 10.1371/journal.pone.0065569. Print 2013.

3.

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J, Gao J, Fang D, Rao Z.

Clinics (Sao Paulo). 2012 Sep;67(9):1093-9.

4.

Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.

Zhang H, Li Z, Wang K.

Oncol Rep. 2014 Apr;31(4):1954-60. doi: 10.3892/or.2014.3026. Epub 2014 Feb 18.

PMID:
24549815
5.

Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.

Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH.

Surgery. 2014 Aug;156(2):270-9. doi: 10.1016/j.surg.2014.04.055. Epub 2014 Jun 19.

PMID:
24953273
6.

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.

Mol Cancer. 2014 Jan 13;13:7. doi: 10.1186/1476-4598-13-7.

7.

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Wei G, Wang M, Hyslop T, Wang Z, Carr BI.

Int J Cancer. 2010 Dec 15;127(12):2949-58. doi: 10.1002/ijc.25498.

8.

Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.

Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1255-64. doi: 10.1007/s00280-013-2120-2. Epub 2013 Feb 23.

PMID:
23435877
9.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

10.

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.

Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, Zhu YY, Qin J.

BMC Cancer. 2013 Nov 6;13:527. doi: 10.1186/1471-2407-13-527.

11.

Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.

Zhai B, Jiang X, He C, Zhao D, Ma L, Xu L, Jiang H, Sun X.

Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.

PMID:
25416439
12.

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.

Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y.

BMC Cancer. 2013 Jul 29;13:363. doi: 10.1186/1471-2407-13-363.

13.

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.

Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.

Br J Pharmacol. 2013 Feb;168(3):658-72. doi: 10.1111/j.1476-5381.2012.02212.x.

14.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, J├╝cker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

15.

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.

Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W.

Br J Cancer. 2013 Jul 23;109(2):342-50. doi: 10.1038/bjc.2013.334. Epub 2013 Jun 27.

16.

Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.

Gao J, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ge YS, Yu JH, Ren WH, Liu WB, Zhang CH.

J Int Med Res. 2010 Jul-Aug;38(4):1413-27.

PMID:
20926014
17.

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.

Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.

Cancer Lett. 2014 Dec 1;355(1):96-105. doi: 10.1016/j.canlet.2014.09.011. Epub 2014 Sep 11.

PMID:
25218350
18.

Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.

Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.

Mol Carcinog. 2009 Jan;48(1):56-65. doi: 10.1002/mc.20455.

PMID:
18506760
19.

PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.

Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.

J Surg Res. 2013 Nov;185(1):225-30. doi: 10.1016/j.jss.2013.05.016. Epub 2013 May 25.

20.

Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.

Honma Y, Shimizu S, Takehara T, Harada M.

J Gastroenterol. 2014 Mar;49(3):517-26. doi: 10.1007/s00535-013-0796-z. Epub 2013 Mar 31.

PMID:
23543326
Items per page

Supplemental Content

Write to the Help Desk